The Balversa Resubmission Journey: From FDA CRL to Approval
Hello Regulatory Scientists, Today, let’s dive into the journey of Balversa (erdafitinib) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Balversa (erdafitinib) Mechanism of Action: FGFR (fibroblast growth factor receptor) inhibitor, […]